ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - varicella virus, live attenuated - אבקה וממס להכנת תמיסה להזרקה - varicella virus, live attenuated nlt 10^3.3 pfu - varicella zoster vaccines - in the event of negative anamnesis, for the active immunisation against varicella in healthy subjects only from the age of 12 months.

ישראל - עברית - Ministry of Health

bayer israel ltd - aflibercept - תמיסה להזרקה לזגוגית העין - aflibercept 40 mg/ml - aflibercept

ישראל - עברית - Ministry of Health

novartis israel ltd - brolucizumab - תמיסה להזרקה - brolucizumab 120 mg / 1 ml - brolucizumab

ישראל - עברית - Ministry of Health

gilead sciences israel ltd - lenacapavir as sodium - תמיסה להזרקה - lenacapavir as sodium 309 mg/ml - lenacapavir

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - urofollitropin - אבקה להכנת תמיסה לזריקה - urofollitropin 75 iu/vial - urofollitropin - urofollitropin - a treatment with fsh followed by the administration of human chronic gonadotrophin (hcg) is indicated to induce ovulation in infertile women suffering from hypothalamus or hypophyseal disorders and in spanomenorrhoeic or amenorrhoeic women. these women belong to the who group ii and have generally already been treated with clomiphene citrate. most have polycystic ovarian syndrome. fsh offers good therapeutic prospects for patients whose lh:fsh ratio has to be adjusted, avoiding an exogenous supply of lh fsh may be used alone or in concomitance with human menopausal gonadotropin (hmg) in order to stimulate multiple follicular growth in patients involved in medically assisted reproduction programs (ivf-et,gift).

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - urofollitropin - אבקה להכנת תמיסה לזריקה - urofollitropin 150 iu/vial - urofollitropin - urofollitropin - a treatment with fsh followed by the administration of human chronic gonadotrophin (hcg) is indicated to induce ovulation in infertile women suffering from hypothalamus or hypophyseal disorders and in spanomenorrhoeic or amenorrhoeic women. these women belong to the who group ii and have generally already been treated with clomiphene citrate. most have polycystic ovarian syndrome. fsh offers good therapeutic prospects for patients whose lh:fsh ratio has to be adjusted, avoiding an exogenous supply of lh fsh may be used alone or in concomitance with human menopausal gonadotropin (hmg) in order to stimulate multiple follicular growth in patients involved in medically assisted reproduction programs (ivf-et,gift).

ישראל - עברית - Ministry of Health

ferring pharmaceuticals ltd - urofollitrophin highly purified (hpfsh) 75 iu/vial - powder for solution for injection - urofollitropin - anovulation (including polycystis ovarian disease (pcod) in women who have been unresponsive to treatment with clomiphene citrate. controlled ovarian hyperstimulation to induce the development of multiple follicles for assisted reproductive technologies (art) (e.g. in vitro fertilisation/embryo transfer (evf/et), gamete intra-fallopian transfer (gift) and intracytoplasmic sperm injection (icsi)).

ישראל - עברית - Ministry of Health

merck serono ltd - follitropin alfa - אבקה להכנת תמיסה לזריקה - follitropin alfa 5.5 mcg/dose - follitropin alfa - follitropin alfa - 1) gonal-f followed by chorionic gonadotrophin (hcg) is recommended for the stimulation of follicular development and ovulation in women with hypothalamic-pituitary dysfunction who present with either oligomenorrhoea or amenorrhoea. these women are classified as w.h.o group ii patients and usually receive clomiphene citrate as primary therapy. they have evidence of endogenous oestrogen production and thus will either spontaneously menstruate or experience withdrawal bleeding after progestagen administration. polycystic ovarian disease (pcod) is part of the who ii classification and is present in the majority of these patients. 2) gonal-f is indicated for stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertillization (ivf) gamete intra-fallopian transfer (gift) and zogote intra-fallopian transfer (zift). 3) gonal-f is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of sperma

ישראל - עברית - Ministry of Health

merck serono ltd - follitropin alfa - תמיסה להזרקה - follitropin alfa 600 iu/ml - follitropin alfa - follitropin alfa - gonal-f followed by chorionic gonadotrophin (hcg), is recommended for the stimulation of follicular development and ovulation in women with hypothalamic-pituitary dysfunction who present with either oligomenorrhoea or amenorrhoea. these women are classified as w.h.o group ii patients and usually receive clomiphene citrate as primary therapy. they have evidence of endogenous oestrogen production and thus will either spontaneously menstruate or experience withdrawal bleeding after progestagen administration. polycystic ovarian disease (pcod) is part of the who ii classification and is present in the majority of these patients. 2) gonal-f is indicated for stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertillization (ivf), gamete intra-fallopian transfer (gift) and zogote intra-fallopian transfer (zift). 3) gonal-f is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermat

ישראל - עברית - Ministry of Health

organon pharma israel ltd., israel - follitropin beta - תמיסה להזרקה - follitropin beta 833 iu / 1 ml - follitropin beta - follitropin beta - puregon is indicated for the treatment of female infertility in the following clinical situations: anovulation (including polycystic ovarian disease, pcod) in women who have beenunresponsive to treatment with clomiphene citrate. controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs [ e.g. in vitro fertilisation/embryo transfer (ivf/et), gamete intra-fallopian transfer (gift) and intracytoplasmic sperm injection (icsi)]. in the male : deficient spermatogenesis due to hypogonadotrophic hypogonadism.